Sign Up
Stories
Biosimilar Partnership in U.S.
Share
Advancements in Cancer Treatment and Mar...
Advicenne's 2024 Financial Calendar and ...
BioArctic's LEQEMBI Wins Awards, Eisai E...
89bio to Present pegozafermin for NASH a...
AB Science's Medical Breakthrough Webcas...
ABBio Innovates Antibody Development
Overview
API
Alvotech and Teva partner with Quallent Pharmaceuticals for the U.S. commercialization of a biosimilar to Humira.
Ask a question
How might this partnership impact the accessibility of biosimilars in the U.S. market?
What challenges could arise in the commercialization process of this high-concentration biosimilar?
What implications does this agreement have for other pharmaceutical companies operating in the U.S.?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Apr 2024
Coverage